KEY ADVANCES IN THE DIAGNOSIS AND MANAGEMENT
OF EOSINOPHILIC ESOPHAGITIS (EOE):
Role of JORVEZA®
(budesonide orally disintegrating tablets)
in the Australian clinical setting
Over April and May 2022, a series of meetings featuring international guest speaker, Professor Stephen Attwood, and local Chairs and Speakers were run with great success in the major Australian capital cities. A total of 174 healthcare professionals attended and participated in the open-forum discussions during each meeting. If you were unable to attend the meetings, you can catch up now by watching the presentations and Q&A sessions, at a time that suits you.
WATCH THE PRESENTATIONS
Clinical Development Program for JORVEZA® in the Treatment of Adults with EoE
Professor Stephen Attwood
Professor of Gastroenterology & Biophotonics, Durham University, UK
Watch the full presentation
Play Video
Play Video
Current Diagnostic and Management Strategies for EoE in Australia
Dr Matthew Remedios - Queensland
Senior Consultant Gastroenterologist, Royal Brisbane and Women’s Hospital, Brisbane Gastroenterologist, Therapeutic Endoscopist, Wesley Gastroenterology and Liver Group, Wesley Hospital, Brisbane
Play Video
Dr Santosh Sanagapalli - New South Wales
Staff Specialist Gastroenterologist and Director, St Vincent’s Centre for Swallowing & Oesophageal Disorders, Sydney
Play Video
Associate Professor Rebecca Burgell - Victoria
Head of the Functional GI Disorder Service, Department of Gastroenterology, Alfred Health, Melbourne
Play Video
Dr Hamish Philpott - South Australia
Gastroenterologist, Northern Adelaide Local Health Network, Adelaide
Play Video
Dr Matthew Smith - Western Australia
Gastroenterologist, Fiona Stanley Hospital, Murdoch, Western Australia
Play Video
Compilation of Q&A sessions from each state-based meeting including Professor Attwood and local speakers and chairs
Play Video
SPEAKER AND CHAIR BIOGRAPHIES
International Speaker
Stephen E. Attwood, MD, FRCSI, is honorary professor in health services research at Durham University in Durham, UK, and an independent consulting advisor on research in oesophageal diseases. Most recently, he was a consultant surgeon at Northumbria Healthcare in Northumberland, UK.
Since identifying EoE and publishing the first description of the disease, Dr Attwood has spent his career caring for patients with EoE, providing minimally invasive treatment for upper gastrointestinal disorders, including endoscopy and laparoscopic surgery. He has been actively engaged in clinical trials of upper gastrointestinal diseases, including budesonide formulations for EoE; the ASPECT trial of cancer prevention in Barrett’s oesophagus; BEST3, a study of Cytosponge screening for Barrett’s oesophagus in general practices; Endobarrier, a UK study of endoscopic antiobesity therapy; the LOTUS trial (surgery vs proton pump inhibitor for reflux therapy); and EndoStim, an electrical neuromodulator of the lower oesophageal sphincter for the treatment of gastroesophageal reflux disease. The author of over 200 publications, including many papers and guidelines on EoE, he is the senior author of the British Society of Gastroenterology Guideline on Therapeutic Dilatation of the Oesophagus (published in 2018) and the European Guidelines on Eosinophilic Oesophagitis (2017). He is also a co-author of the new 2022 British Society of Gastroenterology Guidelines on EoE, published in May 2022.
Local Speakers
Senior Consultant Gastroenterologist, Royal Brisbane and Women’s Hospital, Brisbane
Gastroenterologist, Therapeutic Endoscopist, Wesley Gastroenterology and Liver Group, Wesley Hospital Brisbane
Matthew completed his undergraduate medical degree at the University of Queensland in 1995. He undertook his junior training and subsequent Gastroenterology training, at the Princess Alexandra Hospital, Brisbane and Townsville Hospital, obtaining fellowship of the Royal Australasian College of Physicians in 2003. Matthew completed fellowships in endoscopic retrograde cholangiopancreatography (ERCP) at the Princess Alexandra Hospital before completing an Interventional Endoscopy Fellowship at St Michael’s Hospital Toronto, Canada. During this time, he developed a specific interest in ERCP, Barrett’s oesophagus, resection / ablative techniques and small bowel enteroscopy.
On returning to Australia in 2005, Matthew accepted a position at the Royal Brisbane and Women’s Hospital (RBWH) where he is now a Senior Consultant Gastroenterologist, performing and teaching advanced endoscopy, in particular ERCP, small bowel enteroscopy and Barrett’s management and ablation, including establishing the Barrett’s radiofrequency ablation (RFA) service. Matthew is actively involved in teaching registrars and fellows, as well as in the endoscopic research programme at the RBWH and through his involvement in the Australian New Zealand Endoscopy Leaders Forum (ANZELF), for which he is currently on the organising committee. Matthew is involved in a busy private practice at the Wesley Hospital as a founding member of the Wesley Gastroenterology and Liver Group. He served as a member of the Gastroenterology Society of Australia (GESA) Endoscopy Faculty from 2020 to 2021, before taking up the role as Chair.
Staff Specialist Gastroenterologist and Director, St Vincent’s Centre for Swallowing & Oesophageal Disorders, Sydney
Dr Santosh Sanagapalli is a gastroenterologist and specialist in swallowing disorders. He undertook a clinical research fellowship in gastrointestinal physiology at University College London and completed his PhD at the University of Sydney. He established the Centre for Swallowing & Oesophageal Disorders at St Vincent’s Hospital Sydney, where he runs an active clinical research program. His research is primarily focused on advancing the methodology and utility of the technology used to investigate reflux and swallowing disorders, including high-resolution manometry, endoscopy and barium oesophagography.
Head of the Functional GI Disorder Service, Department of Gastroenterology, Alfred Health, Melbourne
A/Prof Rebecca Burgell is a consultant gastroenterologist at Alfred Health and Monash University in Melbourne, with an interest in functional gastrointestinal disorders, clinical nutrition and inflammatory bowel disease (IBD). She is the Head of the Functional Gastrointestinal Disorders service and Eosinophilic Oesophagitis service at Alfred Health and is actively involved in research in this field.
At present, her research interests include exploring novel models of care for patients with functional bowel disorders, the role of dietary therapy in gastrointestinal disorders, novel therapies and outcomes in EoE, exploring the intraluminal environment in health and disease and the use of intestinal ultrasound in patients with functional bowel disorders.
Gastroenterologist, Northern Adelaide Local Health Network, Adelaide
Dr Hamish Philpott is a gastroenterologist with the Northern Adelaide Local Health Network (NALHN – Modbury and Lyell McEwin Hospitals). He has endoscopy lists at Stirling Hospital, Burnside Hospital, and North-Eastern Hospital, Adelaide. He is also a Senior Clinical Lecturer at the University of Adelaide.
Dr Philpott worked as a consultant gastroenterologist in Melbourne and Central Victoria for six years (2012-2017), both in private practice, and as a visiting specialist at The Alfred Hospital, Eastern Health, Melbourne, and at Bendigo Hospital.
He graduated with a Bachelor of Medicine and Bachelor of Surgery in 2001 from the University of Adelaide, before completing his PhD at Monash University in 2016. During his PhD studies he was supervised by the Head of Luminal Gastroenterology Research, Department of Gastroenterology,
Monash University, Professor Peter Gibson, who co-invented the Low FODMAP diet to help people living with Irritable Bowel Syndrome (IBS) to control their symptoms.
He was then awarded various research and clinical fellowships in the USA and The United Kingdom. He travelled to Augusta, Georgia to undertake a Neurogastroenterology fellowship, and to the University of North Carolina, Chapel Hill to further his research on EoE, in addition to undertaking a clinical preceptorship on functional gastroenterology.
Over the years, Dr Philpott has been the recipient of many grants. He received a National Health and Medical Research Council (NHMRC) scholarship to support his research on EoE and was awarded the 2016/17 Bushell Fellow by the Royal Australasian College of Physicians (RACP). He also received additional funding from GESA in 2018 to further his research into EoE. In addition, he has received research funding from AusEE – a charity dedicated to improving the lives of those affected by eosinophilic diseases – to further his research on food allergies.
Dr Philpott has authored more than 60 peer-reviewed publications, and serves as a reviewer for multiple journals, such as Clinical Gastroenterology, Hepatology and Clinical & Experimental Allergy.
Dr Matthew Smith is a Gastroenterologist and Fiona Stanley Hospital in Western Australia
Local Chairs
Clinical Director of Endoscopy, Royal Brisbane and Women’s Hospital (RBWH), Brisbane
Dr Grimpen attended university in Göttingen, Germany, where he attained his MBBS equivalent and MD. He trained in gastroenterology in Canberra, with fellowships in Sydney and Brisbane, before becoming a staff specialist at RBWH. He is one of the Deputy Directors of Gastroenterology and Hepatology at the RBWH, and has been the Clinical Director of Endoscopy for a number of years, specialising in interventional endoscopy, including hepatobiliary and small bowel work. Dr Grimpen supervises the competitive Interventional Endoscopy Fellowship program at the RBWH, and leads or is otherwise involved in multiple research projects ranging from upper GI, pancreatobiliary, small bowel, and colonoscopy research questions. He supervises several regular outpatient clinics at the RBWH, where he is one of the consultants with a special interest in EoE.
Prof Katelaris’ major research interests have been in luminal gastroenterology, including Helicobacter pylori infection, gastro-oesophageal reflux disease (GORD), IBD and bowel cancer. He is widely published and a frequently invited national and international speaker. He has been actively involved in national and international working parties and guideline formulation over many years. He is recognised by his peers as an experienced clinician, endoscopist, researcher and educator.
He was the awarded the GESA Outstanding Clinician Award in 2019.
Dr Nandurkar completed his Gastroenterology training in NSW and an Oesophageal Fellowship at the Mayo Clinic, USA. He is a Senior Lecturer at Monash University and involved in teaching medical students and supervising gastroenterology training. His clinical and research interests include, oesophageal diseases such as GORD, EoE, Barrett’s in addition to IBS and gastrointestinal motility.
Gastroenterologist in public, private and rural practice
Dr. Tam holds an academic appointment at the University of Adelaide, as well as several honorary professorships overseas. He is an active member of GESA and has served as past chair of the Endoscopy Faculty. As a faculty member of the National Endoscopy Training Initiative of GESA, Dr Tam is committed to promoting safety and quality in endoscopy. He also chaired the Australian Council of Healthcare Standards for Gastrointestinal Endoscopy Clinical Indicators in 2018. His interests include, gastrointestinal malignancies, endoscopic imaging and interventional endoscopy. He is on the editorial board of Endoscopic Ultrasound journal and is involved in national and international educational meetings and webinars. Dr Tam is past president of the Australian Medical Association (South Australia) and is on the Board of the State and Federal AMA.
Dr Singh completed his graduate medical training in India. He moved to Perth to complete his basic physician training and advanced training in Gastroenterology in Perth. He was awarded Fellowship of the Royal Australasian College of Physicians in 2014. After completing his Advanced Gastroenterology training, he undertook advanced clinical and research fellowship in IBD from Exeter, UK, focusing on management of complex IBD as well as research into various aspects of IBD management including IBD pharmacogenetics. He has subspeciality interest in luminal inflammatory conditions including IBD coeliac disease and EoE.
Never miss an event. Visit www.events.drfalkpharma.com.au
Please review product information before prescribing, JORVEZA® available here.
This content is intended for Healthcare Professionals only.
Copyright® 2022 Dr Falk Pharma Australia Pty Ltd. ABN 40 631 091 131.
Level 10, 815 Pacific Highway, Chatswood NSW 2067.
Website: www.drfalkpharma.com.au
Tel: 1800 DRFALK (1800 373 255). Email: www.drfalkpharma.com.au
Date of preparation May 2022. EOE-2022-1108. DRFAL1925.
Copyright® 2022 Dr Falk Pharma Australia Pty Ltd. ABN 40 631 091 131.
Level 10, 815 Pacific Highway, Chatswood NSW 2067.
Website: www.drfalkpharma.com.au
Tel: 1800 DRFALK (1800 373 255). Email: www.drfalkpharma.com.au
Date of preparation May 2022. EOE-2022-1108. DRFAL1925.